HIKAL LIMITED Fair Value
HIKAL · Healthcare · Current price ₹201.98
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹85 | 3% ROE fading to 13% over ~3 yrs, on ₹97 book |
| Relative P/E | — | Needs positive EPS |
| Graham floor | — | Needs positive EPS |
| Analyst target | ₹300 | Street consensus 12-month target price |
Is HIKAL LIMITED undervalued?
DocStoX estimates the fair value of HIKAL LIMITED at ₹145 per share, versus the current market price of ₹202. That puts the stock about -28.1% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 2 independent methods: Residual income (₹85), Analyst target (₹300). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹85 (bear) to ₹145 (base) to ₹300 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on HIKAL LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.